|
|
Aytu Biopharma Inc (NASDAQ: AYTU) |
|
Price: $1.2500
$0.02 
1.215%
|
| Day's High:
| $1.25
| Week Perf:
| 0.81 %
|
| Day's Low: |
$ 1.24 |
30 Day Perf: |
-2.34 % |
| Volume (M): |
1 |
52 Wk High: |
$ 3.45 |
| Volume (M$): |
$ 1 |
52 Wk Avg: |
$2.25 |
| Open: |
$1.24 |
52 Wk Low: |
$1.15 |
|
|
| Market Capitalization (Millions $) |
11 |
| Shares
Outstanding (Millions) |
8 |
| Employees |
15 |
| Revenues (TTM) (Millions $) |
68 |
| Net Income (TTM) (Millions $) |
-5 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Aytu Biopharma Inc
Aytu BioPharma Inc. is a specialty pharmaceutical company that focuses on developing and commercializing innovative products in the areas of urology, women's health, and sleep disorders. The company is headquartered in Englewood, Colorado and was founded in 201
The company's urology product portfolio includes Natesto, a nasal testosterone replacement therapy (TRT) for adult males diagnosed with hypogonadism; ProstaScint, a radioactive imaging agent for prostate cancer detection; and MiOXSYS, a male infertility diagnostic platform that measures oxidative stress levels in semen samples.
In the women's health sector, Aytu BioPharma produces Tuzistra XR, an extended-release cough syrup designed to treat acute coughing symptoms. The company also recently acquired a product called ZolpiMist, a prescription sleep aid that delivers a fine mist of zolpidem tartrate, which is a sedative-hypnotic drug.
Aytu BioPharma has a diverse and robust pipeline of products in various stages of development that target diseases in urology, endocrinology, and infectious diseases. The company has several strategic collaborations, including a licensing agreement with Acerus Pharmaceuticals for the distribution of Natesto in Canada and a partnership with Innovus Pharmaceuticals for the development and commercialization of products in women's health.
Aytu BioPharma is committed to improving patient outcomes by providing innovative and effective treatments for unmet medical needs. The company has a strong financial position, with a cash balance of $24 million as of June 30, 2020, and has recently reported positive revenue growth. Additionally, Aytu BioPharma has been actively involved in efforts to combat COVID-19, with the distribution of a rapid COVID-19 test and the acquisition of certain assets from Cerecor Inc. for the development of a COVID-19 treatment.
Company Address: 7900 East Union Avenue, Suite 920 Denver 80237 CO
Company Phone Number: 437-6580 Stock Exchange / Ticker: NASDAQ AYTU
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Aytu Biopharma Inc
Aytu Biopharma Inc, a pharmaceutical company based in the United States, experienced a decline in demand during the financial span ending March 31, 2024. This led to an increase in the company's deficit, with a deficit per share advancing to $-0.52 from $-1.93. Additionally, the company's revenue decreased by 22.17% to $17.69 million from $22.73 million compared to the previous year.
In contrast, the second quarter of the fiscal year saw a slightly lesser decline in revenue, with a decrease of 20.313% from $22.20 million. However, the deficit per share surged from $-0.04 in the previous quarter. The most recent fiscal period reported a net deficit of $-2.887 million, compared to a deficit of $-7.200 million in the same reporting period a year ago.
|
| Aytu Biopharma Inc
In the fiscal year ending December 31, 2023, Aytu Biopharma Inc. (AYTU) showed improvements in its financial results compared to the previous year. The company was able to reduce its losses significantly, with a shortfall per share of $-0.04, compared to $-2.15 in the previous year. Additionally, AYTU's revenue decreased by -15.51% to $22.20 million, down from $26.28 million in the same reporting period the year before.
Looking at the bigger picture, income per share saw an improvement from $-1.48 per share, while revenue grew by 1.923% from $21.78 million. This indicates a positive trend in the company's financial performance over time.
|
| Aytu Biopharma Inc
Over the past week, Aytu Biopharma Inc shares experienced a significant decline of -13.03%. This drop contributes to the company's remarkable year to date performance, which stands at an impressive 1253.27%. Aytu Biopharma Inc shares are currently being traded on the NASDAQ, trading 35.1% above its 52-week average.
The decline in share price can be attributed to weak business performance during the most recent fiscal period. Aytu Biopharma Inc incurred greater losses, resulting in a net deficit per share of $-1.48 as compared to $-0.28 in the previous year. Additionally, the company witnessed a decline in revenue by -21.229%, amounting to $21.78 million compared to $27.66 million in the previous year.
|
| Aytu Biopharma Inc
Bearish Outlook for Aytu Biopharma Inc. as Shortfall per Share and Net Losses Widen
Aytu Biopharma Inc, a pharmaceutical company, recently released its financial results for the time-frame ending June 30, 2023, showing a concerning trend of widening losses. Despite a small increase in revenue, the company's shortfall per share has extended to $-0.61 from $-0.49 year on year.
The financial statement also reveals that Aytu Biopharma Inc reported a net shortfall of $-2.457 million for the period, a significant improvement from the $-17.701 million deficit reported in the same period the previous year. While this may seem like a positive sign, it is important to note that the company is still operating at a loss.
|
| Aytu Biopharma Inc
Aytu Biopharma Inc is a well-known name in the healthcare sector. The company's main area of focus is to develop cutting-edge technologies and innovative products that can improve the lives of people all around the world. Despite the recent financial losses, the company is determined to bring groundbreaking medical solutions to the market and have a positive effect on the healthcare industry.
The third quarter of 2023 earnings season has been challenging for Aytu Biopharma Inc. The company registered a loss of $-1.93 per share, which was higher than the previous year. However, on a positive note, the earnings per share (EPS) improved from $-2.15 per share compared to the preceding reporting season. The revenue for the company sank by -6.058% to $22.73 million from $24.20 million in the same reporting season one year ago. Furthermore, sequentially the revenue deteriorated by -13.494% from $26.28 million. The reported net deficit was $-7.200 million in the recent financial year, instead of a deficit of $-53.073 million in the same reporting season a year ago.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.55 $ |
| Revenues (TTM) |
8.06 $
|
| Cash Flow (TTM) |
0.1 $ |
| Cash |
2.4 $
|
| Book Value |
3.63 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.55 $
|
| Revenues (TTM) |
8.06 $ |
| Cash Flow (TTM) |
0.1 $ |
| Cash |
2.4 $
|
| Book Value |
3.63 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Rx Segment |
|
 102.76 % |
of total Revenue |
| Rx ADHD Portfolio |
|
87.52 % |
of total Revenue |
| Rx The Pediatric Portfolio |
|
15.2 % |
of total Revenue |
| Rx Product and Service Other |
|
0.03 % |
of total Revenue |
|
|
5.63% 